Related Experiment Video

Updated: Jun 23, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Percutaneous transluminal dilatation in the treatment of renal vascular hypertension

C E Grim, F C Luft, H Y Yune

    Annals of Internal Medicine
    |October 1, 1981
    PubMed

    Insights

    Percutaneous transluminal dilatation effectively treated renal vascular hypertension in fibromuscular disease patients. Atherosclerotic disease patients experienced higher restenosis rates and lower cure rates after this intervention.

    Area of Science:

    • Cardiovascular Medicine
    • Interventional Radiology

    Background:

    • Renal vascular hypertension is a significant cause of secondary hypertension.
    • Percutaneous transluminal dilatation (PTD) is an established treatment for renal artery stenosis.

    Purpose of the Study:

    • To evaluate the long-term efficacy and recurrence rates of PTD in patients with renal vascular hypertension.
    • To compare outcomes between patients with fibromuscular disease and atherosclerotic disease.

    Main Methods:

    • Twenty-six patients with renal vascular hypertension underwent PTD.
    • Twenty-one patients were followed for over 1 year, with 18 undergoing repeat angiography.
    • Outcomes were stratified based on the underlying etiology of renal artery stenosis.

    Main Results:

    • Restenosis occurred in 1 of 6 patients with fibromuscular disease versus 12 of 12 patients with atherosclerotic disease.
    • Hypertension cure rates were higher in fibromuscular disease (6/10) compared to atherosclerotic disease (1/16).
    • PTD demonstrated advantages in simplicity, cost, and reduced risk.

    Conclusions:

    • PTD is a viable treatment for renal vascular hypertension, particularly in fibromuscular disease.
    • Long-term utility requires further investigation, potentially through prospective randomized trials or registries.
    • Atherosclerotic renal artery stenosis carries a higher risk of restenosis and lower likelihood of cure post-PTD.

    More Related Videos

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

    Published on: June 6, 2025

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

    Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

    Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
    Continuous Renal Replacement Therapy01:30

    Continuous Renal Replacement Therapy

    Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
    Imaging Studies VII: Vascular Imaging01:19

    Imaging Studies VII: Vascular Imaging

    DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...